Teklistamab with the latest two-year effi cacy and safety data in the treatment of RRMM
Published in:
Transfuze Hematol. dnes,29, 2023, No. 3, p. 207-209.
Category:
doi:
https://doi.org/10.48095/cctahd2023207
Overview
Teklistamab is the fi rst-in-class bispecifi c antibody against B-cell maturation antigen (BCMA) and CD3 receptor on the surface of T-lymphocytes used in the treatment of relapsed/ refractory multiple myeloma (RRMM). New long-term data demonstrate its sustained effi cacy in achieving deep therapeutic responses and maintaining them over time, even with an extended 2-week dosing regimen.
Keywords:
treatment response – Safety – overall survival – minimal residual disease – teklistamab – bispecifi c antibody – B-cell maturation antigen – CD3 T-lymphocytes – relapsed/ refractory multiple myeloma – progression-free survival
Sources
1. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016; 175 (2): 252–264.
2. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere 2021; 5 (2): e528.
3. Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in on-cology. J Natl Compr Canc Netw. 2020; 18 (12): 1685–1717.
4. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022; 36 (5): 1371–1376.
5. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387 (6): 495–505
6. Souhrn údajů o přípravku Tecvayli. [online]. Dostupné z: www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_cs.pdf.
7. Usmani S, et al. Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL, USA & Virtual.
8. van de Donk N, et al. Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2–6, 2023; Chicago, IL, USA & Virtual (Poster #8011) .
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 3
Most read in this issue
- Hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease)
- Boris Bubeník slaví sedmdesátiny
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia – cardiovascular complications and bleeding
- Covid score – the contribution in prognostic stratification of patients with COVID-19